性感染症診断薬市場：疾患タイプ、検査タイプ、サンプルタイプ、エンドユーザー、流通チャネル別-2025-2030年世界予測

性感染症診断薬市場は、2024年には127億8,000万米ドルとなり、2025年には135億3,000万米ドル、CAGR6.03%で成長し、2030年には181億7,000万米ドルに達すると予測されています。

性感染症（STDs）診断のダイナミックな分野では、絶え間ない技術革新と進化するヘルスケア慣行が、疾患の検出・管理方法を再構築しています。STDの世界の負担が増加し続ける中、迅速かつ正確で利用しやすい診断ソリューションの必要性がかつてないほど高まっています。最新の診断技術は精度を向上させるだけでなく、検査時間を大幅に短縮し、早期治療と予防への道を開いています。この包括的なサマリーでは、市場に影響を与える主な促進要因の詳細な概要を提供し、セグメンテーションと地域別の業績に関する洞察を提供し、この重要な分野に従事する企業の戦略的方向性を明らかにします。

技術の進歩と診断手順が統合された現在の段階は、従来の診療を変革しつつあります。検査室専門家や臨床医から公衆衛生戦略家に至るまで、利害関係者は精密さと迅速な対応を特徴とする時代の恩恵を受けています。この後のセクションで述べるように、診断の現場は、市場力学と患者ケアに影響を与える大きな変革期を迎えています。本レポートは、臨床ニーズと技術革新の間の複雑な相互作用をナビゲートしようとする意思決定者にとって不可欠な最近のデータと動向をもとに、こうしたシフトに光を当てるものです。

性感染症診断薬市場の変革

近年、技術面、規制面、市場面における変革的なシフトがSTI診断薬業界を再定義しています。分子生物学とデジタル解析の進歩は、ポイントオブケアと検査室での検査方法の急速な強化につながりました。これらの技術革新は診断精度を高め、検査期間を短縮し、多様な患者集団にとって検査がより身近なものとなりました。これと並行して、規制の枠組みや償還政策の変化により、市場参入企業に新たな機会がもたらされる一方、既存企業は製品ポートフォリオの再調整を迫られています。

核酸増幅技術や迅速血漿再評価アッセイなどの新技術は、今や次世代診断薬のバックボーンとなっています。これらの技術は、データ解釈や遠隔モニタリングのためのデジタルシステムとの統合の進展と相まって、臨床医がより多くの情報に基づいた意思決定を行うことを可能にしています。この進化は臨床応用だけにとどまらず、市場力学にも及んでおり、患者の属性や地域のヘルスケアインフラの両方に合わせた個別化診断ソリューションへのシフトが見られます。競合情勢がこのような新たな動向に適応していく中で、利害関係者は継続的なイノベーションを促されており、サービス提供のペースが診断能力の急速な進歩に見合うようになることが求められています。

STI診断の主要セグメントに関する洞察

市場セグメンテーションの詳細分析により、STI診断エコシステムを特徴づける多様な側面を明確に理解することができます。クラミジア、淋病、単純ヘルペスウイルス（HSV）、ヒト免疫不全ウイルス（HIV）、ヒトパピローマウイルス（HPV）、梅毒を含む主要病原体を調査し、疾患タイプに基づいて市場を解剖します。この詳細な分類により、集団発生の発生率、人口統計学的影響、地域的有病率における明確なパターンが明らかになりました。検査の種類に関する調査では、検査室検査とポイントオブケア検査の対比に焦点を当てています。検査室検査は、酵素結合免疫吸着測定法（ELISA）、核酸増幅検査（NAAT）、迅速血漿反応検査（RPR）などの確立された技術によって広範に研究されており、一方、ポイントオブケア検査には、家庭用検査キットや迅速検査などのツールが含まれます。サンプルの種類に基づく調査では、血液、尿、膣スワブの診断有用性を調べ、各サンプルに関連する異なる感度と特異性を強調します。セグメンテーションは、在宅医療、病院・診療所、ポイント・オブ・ケアから公衆衛生研究所、調査研究室まで、エンドユーザー・プロファイルに関する分析で続いています。最後に、市場を流通チャネル別にさらに細分化し、直販と代理店網を比較することで、市場への浸透度とサービス提供の効率性を明らかにします。このような微妙なセグメンテーション研究は、各市場セグメントに固有の複雑さと個別のニーズを浮き彫りにし、診断戦略や投資に影響を与えています。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で性感染症の発生率と認知度が上昇
    • 政府や保健機関による支援政策や取り組みの実施の増加
    • ヘルスケアサービスへのアクセスが拡大し、世界中で性感染症診断サービスの利用と利用が拡大します。
  • 抑制要因
    • 進化する菌株や新たな病原体に合わせて診断検査を最新の状態に保つ能力に関連する問題
  • 機会
    • 診断会社とヘルスケア提供者またはNGOとの提携による成長の可能性
    • 専門の研究所やヘルスケア従事者の必要性を減らすためのポイントオブケア検査の革新
  • 課題
    • さまざまな地域にまたがる複雑な規制環境に関連する懸念
• 市場セグメンテーション分析
  • 疾患タイプ：クラミジアの核酸増幅検査は感度と特異性が高いため、その必要性が高まっている
  • エンドユーザー：病院や診療所における性感染症診断のアプリケーションが急増し、正確でタイムリーな診断が可能に
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 性感染症診断薬市場：疾患タイプ別

• クラミジア
• 淋病
• 単純ヘルペスウイルス（HSV）
• ヒト免疫不全ウイルス（HIV）
• ヒトパピローマウイルス（HPV）
• 梅毒

第7章 性感染症診断薬市場テストの種類別

• 臨床検査
  • 酵素免疫測定法（ELISA）
  • 核酸増幅検査（NAAT）
  • 迅速血漿レアギン（RPR）
• ポイントオブケア検査
  • 家庭用検査キット
  • ラピッドテスト

第8章 性感染症診断薬市場サンプルタイプ別

• 血
• 尿
• 膣スワブ

第9章 性感染症診断薬市場：エンドユーザー別

• ホームケア設定
• 病院・クリニック
• ポイントオブケア設定
• 公衆衛生研究所
• 調査室

第10章 性感染症診断薬市場：流通チャネル別

• 直接販売
• 販売代理店

第11章 南北アメリカの性感染症診断薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の性感染症診断薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの性感染症診断薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Astra Biotech GmbH
• Becton Dickinson and company
• Bio-Rad Laboratories, Inc.
• bioMerieux SA
• Danaher Corporation
• Daye Limited
• Diasorin S.p.A
• F. Hoffmann-La Roche Ltd.
• Geneproof
• Hologic Inc.
• Jiangsu BioPerfectus Technologies Co., Ltd
• Liferiver Bio-Tech Corp.
• MedMira Inc.
• Merck KGaA
• Meridian Bioscience Inc.
• Mylab Discovery Solutions Pvt. Ltd.
• Novartis AG
• OraSure Technologies, Inc.
• Qiagen Inc.
• Quest Consumer Inc.
• Sansure Biotech Inc.
• Seegene Inc.
• Siemens Healthineers AG
• Thermo Fisher Scientific, Inc.

LIST OF FIGURES

• FIGURE 1. SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET MULTI-CURRENCY
• FIGURE 2. SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET MULTI-LANGUAGE
• FIGURE 3. SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET RESEARCH PROCESS
• FIGURE 4. SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
• FIGURE 17. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 19. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 21. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 26. SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 27. SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET DYNAMICS
• TABLE 7. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY GONORRHEA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV), BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY HUMAN IMMUNODEFICIENCY VIRUS (HIV), BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY HUMAN PAPILLOMAVIRUS (HPV), BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SYPHILIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS (NAATS), BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY RAPID PLASMA REAGIN (RPR), BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY HOME TESTING KITS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY RAPID TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY VAGINAL SWABS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY PUBLIC HEALTH LABS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 44. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
• TABLE 47. ARGENTINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 48. ARGENTINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 49. ARGENTINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 50. ARGENTINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 51. ARGENTINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 53. BRAZIL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
• TABLE 54. BRAZIL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 55. BRAZIL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 56. BRAZIL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 57. BRAZIL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 58. BRAZIL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 59. CANADA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 60. CANADA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
• TABLE 61. CANADA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 62. CANADA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 63. CANADA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 64. CANADA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. CANADA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 66. MEXICO SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 67. MEXICO SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
• TABLE 68. MEXICO SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 69. MEXICO SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 70. MEXICO SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 71. MEXICO SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. MEXICO SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 73. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 74. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
• TABLE 75. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 76. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 77. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 78. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 79. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 80. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 81. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 82. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
• TABLE 83. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 84. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 85. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 86. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 87. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 88. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 89. AUSTRALIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 90. AUSTRALIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
• TABLE 91. AUSTRALIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 92. AUSTRALIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 93. AUSTRALIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 94. AUSTRALIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 95. AUSTRALIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 96. CHINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 97. CHINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
• TABLE 98. CHINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 99. CHINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 100. CHINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 101. CHINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 102. CHINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 103. INDIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 104. INDIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
• TABLE 105. INDIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 106. INDIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 107. INDIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 108. INDIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 109. INDIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 110. INDONESIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 111. INDONESIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
• TABLE 112. INDONESIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 113. INDONESIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 114. INDONESIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 115. INDONESIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 116. INDONESIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 117. JAPAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 118. JAPAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
• TABLE 119. JAPAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 120. JAPAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 121. JAPAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 122. JAPAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 123. JAPAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 124. MALAYSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 125. MALAYSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
• TABLE 126. MALAYSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 127. MALAYSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 128. MALAYSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 129. MALAYSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. MALAYSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 131. PHILIPPINES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 132. PHILIPPINES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
• TABLE 133. PHILIPPINES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 134. PHILIPPINES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 135. PHILIPPINES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 136. PHILIPPINES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 137. PHILIPPINES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 138. SINGAPORE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 139. SINGAPORE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
• TABLE 140. SINGAPORE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 141. SINGAPORE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 142. SINGAPORE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 143. SINGAPORE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 144. SINGAPORE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 145. SOUTH KOREA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 146. SOUTH KOREA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
• TABLE 147. SOUTH KOREA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 148. SOUTH KOREA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 149. SOUTH KOREA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 150. SOUTH KOREA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 151. SOUTH KOREA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 152. TAIWAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 153. TAIWAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
• TABLE 154. TAIWAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 155. TAIWAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 156. TAIWAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 157. TAIWAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 158. TAIWAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 159. THAILAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 160. THAILAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
• TABLE 161. THAILAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 162. THAILAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 163. THAILAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 164. THAILAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 165. THAILAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 166. VIETNAM SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 167. VIETNAM SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
• TABLE 168. VIETNAM SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 169. VIETNAM SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 170. VIETNAM SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 171. VIETNAM SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 172. VIETNAM SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 173. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 174. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
• TABLE 175. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 176. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 177. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 178. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 179. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 180. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 181. DENMARK SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 182. DENMARK SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
• TABLE 183. DENMARK SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 184. DENMARK SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 185. DENMARK SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 186. DENMARK SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 187. DENMARK SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 188. EGYPT SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 189. EGYPT SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
• TABLE 190. EGYPT SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 191. EGYPT SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 192. EGYPT SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 193. EGYPT SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 194. EGYPT SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 195. FINLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 196. FINLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
• TABLE 197. FINLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 198. FINLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 199. FINLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 200. FINLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 201. FINLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 202. FRANCE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 203. FRANCE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
• TABLE 204. FRANCE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 205. FRANCE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 206. FRANCE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 207. FRANCE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 208. FRANCE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 209. GERMANY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 210. GERMANY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
• TABLE 211. GERMANY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 212. GERMANY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 213. GERMANY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 214. GERMANY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 215. GERMANY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 216. ISRAEL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 217. ISRAEL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
• TABLE 218. ISRAEL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 219. ISRAEL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 220. ISRAEL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 221. ISRAEL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 222. ISRAEL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 223. ITALY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 224. ITALY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
• TABLE 225. ITALY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 226. ITALY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 227. ITALY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 228. ITALY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 229. ITALY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 230. NETHERLANDS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 231. NETHERLANDS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
• TABLE 232. NETHERLANDS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 233. NETHERLANDS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 234. NETHERLANDS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 235. NETHERLANDS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 236. NETHERLANDS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 237. NIGERIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 238. NIGERIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
• TABLE 239. NIGERIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 240. NIGERIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 241. NIGERIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 242. NIGERIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 243. NIGERIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 244. NORWAY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 245. NORWAY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
• TABLE 246. NORWAY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 247. NORWAY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 248. NORWAY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 249. NORWAY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 250. NORWAY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 251. POLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 252. POLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
• TABLE 253. POLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 254. POLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 255. POLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 256. POLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 257. POLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 258. QATAR SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 259. QATAR SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
• TABLE 260. QATAR SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 261. QATAR SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 262. QATAR SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 263. QATAR SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 264. QATAR SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 265. RUSSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 266. RUSSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
• TABLE 267. RUSSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 268. RUSSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 269. RUSSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 270. RUSSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 271. RUSSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 272. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 273. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
• TABLE 274. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 275. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 276. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 277. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2

The Sexually Transmitted Diseases Diagnostics Market was valued at USD 12.78 billion in 2024 and is projected to grow to USD 13.53 billion in 2025, with a CAGR of 6.03%, reaching USD 18.17 billion by 2030.

In the dynamic field of sexually transmitted diseases (STDs) diagnostics, constant innovation and evolving healthcare practices are reshaping how diseases are detected and managed. As the global burden of STDs continues to rise, the need for prompt, accurate, and accessible diagnostic solutions has never been more critical. Modern diagnostic technologies are not only improving accuracy but are also drastically reducing turnaround times, paving the way for early treatment and prevention. This comprehensive summary provides an in-depth overview of the key drivers influencing the market, offers insights into segmentation and regional performance, and highlights strategic directions for companies engaged in this critical space.

The current stage of integration between technological advancements and diagnostic procedures is transforming traditional practices. Stakeholders, ranging from laboratory professionals and clinicians to public health strategists, are benefiting from an era marked by precision and rapid response. As we explore in subsequent sections, the diagnostic landscape is undergoing significant transformative shifts that influence market dynamics and patient care. This report sheds light on these shifts, drawing on recent data and trends essential for decision-makers looking to navigate the complex interplay between clinical needs and technological innovations.

Transformative Shifts in the STI Diagnostics Industry Landscape

Over recent years, transformative shifts across technological, regulatory, and market dimensions have redefined the STI diagnostics industry. Advances in molecular biology and digital analytics have led to rapid enhancements in point-of-care and laboratory testing modalities. These innovations have bolstered diagnostic accuracy, reduced testing timeframes, and made testing more accessible to diverse patient populations. In parallel, changes in regulatory frameworks and reimbursement policies have opened up new opportunities for market entrants, while prompting established companies to recalibrate their product portfolios.

Emerging technologies such as nucleic acid amplification techniques and rapid plasma reevaluation assays now serve as the backbone for next-generation diagnostics. These technologies, coupled with the increasing integration of digital systems for data interpretation and remote monitoring, are enabling clinicians to make more informed decisions. This evolution is not limited to clinical application alone; it extends to market dynamics as well, with an observable shift towards personalized diagnostic solutions that are tailored to both patient demographics and regional healthcare infrastructures. As competitive landscapes adjust to these emerging trends, stakeholders are urged to innovate continuously, ensuring that the pace of service delivery matches the rapid advances in diagnostic capabilities.

Key Segmentation Insights in STI Diagnostics

A detailed analysis of market segmentation provides a clear understanding of the diverse dimensions characterizing the STI diagnostics ecosystem. The market is dissected based on disease type, examining key pathogens including Chlamydia, Gonorrhea, Herpes Simplex Virus (HSV), Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV), and Syphilis. This detailed categorization reveals distinct patterns in outbreak incidences, demographic impacts, and regional prevalence. In our investigation of test types, the focus is on the contrast between laboratory testing and point-of-care testing. Laboratory testing is extensively researched through established techniques such as Enzyme-linked Immunosorbent Assays (ELISA), Nucleic Acid Amplification Tests (NAATs), and Rapid Plasma Reagin (RPR), while point-of-care testing encompasses tools including home testing kits and rapid tests. An exploration based on sample type looks into the diagnostic utility of blood, urine, and vaginal swabs, highlighting different sensitivities and specificities pertinent to each sample. The segmentation continues with an analysis on end-user profiles, ranging from homecare settings, hospitals and clinics, and point-of-care settings to public health labs and research laboratories. Finally, the market is further segmented by distribution channel, comparing direct sales with distributor networks to elucidate market penetration and service delivery efficiencies. These nuanced segmentation studies underline the complexity and tailored needs inherent to each market segment, influencing diagnostic strategies and investments.

Based on Disease Type, market is studied across Chlamydia, Gonorrhea, Herpes Simplex Virus (HSV), Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV), and Syphilis.

Based on Test Types, market is studied across Laboratory Testing and Point-of-Care Testing. The Laboratory Testing is further studied across Enzyme-linked Immunosorbent Assay (ELISA), Nucleic Acid Amplification Tests (NAATs), and Rapid Plasma Reagin (RPR). The Point-of-Care Testing is further studied across Home Testing Kits and Rapid Tests.

Based on Sample Type, market is studied across Blood, Urine, and Vaginal Swabs.

Based on End-User, market is studied across Homecare Settings, Hospitals & Clinics, Point-of-Care Settings, Public Health Labs, and Research Laboratories.

Based on Distribution Channel, market is studied across Direct Sales and Distributors.

Regional Dynamics Shaping the STI Diagnostics Market

The global STI diagnostics market exhibits varied growth trajectories influenced by regional healthcare frameworks and economic priorities. The Americas are witnessing rapid adoption of advanced diagnostic tools driven by an increasing emphasis on early detection and preventive care. In addition, regulatory support and robust healthcare infrastructure are accelerating the integration of innovative testing methodologies, making the region one of the most dynamic in the current landscape. Europe, the Middle East, and Africa collectively present a diverse set of challenges and opportunities. European markets lead in regulatory compliance and technological advancements, while the Middle East and Africa provide emerging markets with significant unmet diagnostic needs. Each of these regions is responding to local challenges by adopting scalable diagnostic solutions that resonate with public health strategies. The Asia-Pacific region, characterized by rapid economic growth and a burgeoning population, is increasingly focusing on the implementation of cost-effective and accessible diagnostic platforms. Region-specific trends, workforce capabilities, and healthcare investments are all influencing the manner in which diagnostics evolve to meet distinct regional requirements. Together, these regional insights offer a comprehensive view of the disparate yet interconnected elements that drive market innovation and expansion on a worldwide scale.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Leading Companies and Their Impact on Diagnostic Innovations

The STI diagnostics market landscape is highly competitive, with several prominent companies driving technological advancements and market growth. Industry leaders such as Abbott Laboratories, Astra Biotech GmbH, Becton Dickinson and company, Bio-Rad Laboratories, Inc., and bioMerieux SA are at the forefront of innovation, developing robust tools and platforms that redefine diagnostic accuracy. In addition, powerhouses like Danaher Corporation, Daye Limited, Diasorin S.p.A, F. Hoffmann-La Roche Ltd., and Geneproof continue to build upon rich legacies in diagnostic research and clinical application. The influence of companies such as Hologic Inc., Jiangsu BioPerfectus Technologies Co., Ltd, Liferiver Bio-Tech Corp., and MedMira Inc. is reflected in their rapid adoption of state-of-the-art diagnostic technologies, contributing to enhanced patient outcomes across multiple regions. Furthermore, distinguished names like Merck KGaA, Meridian Bioscience Inc., Mylab Discovery Solutions Pvt. Ltd., Novartis AG, OraSure Technologies, Inc., Qiagen Inc., Quest Consumer Inc., Sansure Biotech Inc., Seegene Inc., Siemens Healthineers AG, and Thermo Fisher Scientific, Inc. are emblematic of the drive toward innovation and comprehensive disease management. These companies are continuously pushing the boundaries of diagnostic science, with ongoing investments in research and development fostering an ecosystem that supports both rapid technological innovations and strategic collaborations across the healthcare network.

The report delves into recent significant developments in the Sexually Transmitted Diseases Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astra Biotech GmbH, Becton Dickinson and company, Bio-Rad Laboratories, Inc., bioMerieux SA, Danaher Corporation, Daye Limited, Diasorin S.p.A, F. Hoffmann-La Roche Ltd., Geneproof, Hologic Inc., Jiangsu BioPerfectus Technologies Co., Ltd, Liferiver Bio-Tech Corp., MedMira Inc., Merck KGaA, Meridian Bioscience Inc., Mylab Discovery Solutions Pvt. Ltd., Novartis AG, OraSure Technologies, Inc., Qiagen Inc., Quest Consumer Inc., Sansure Biotech Inc., Seegene Inc., Siemens Healthineers AG, and Thermo Fisher Scientific, Inc.. Strategic Recommendations for Industry Leaders in STI Diagnostics

In light of the critical shifts and segmentation complexities inherent in the STI diagnostics market, industry leaders are encouraged to adopt a series of actionable strategies. Foremost, it is imperative that companies invest in the advancement of both molecular diagnostic technologies and digital analytic platforms that not only enhance operational efficiency but also ensure timely and precise results. This involves a reallocation of resources towards research and development, with a focus on emerging technologies that have demonstrated potential in enhancing sensitivity and specificity. In parallel, firms should consider strategic collaborations with regulatory bodies and academic institutions to streamline the translation of innovative diagnostic technologies into market-ready solutions. Capitalizing on regional strengths and diversifying distribution strategies is essential, particularly by leveraging the heterogeneous needs of diverse customer segments identified through the segmentation studies. Enhancing communication channels with end-user groups such as hospitals, public health labs, and homecare settings will further ensure that the developed diagnostic tools meet practical clinical needs. Additionally, a measured expansion into emerging markets, supported by localized product adaptations and pricing strategies, will drive sustainable growth. A cohesive strategy merging technological innovation with effective market penetration and strategic partnerships is likely to secure a competitive edge in this rapidly evolving field.

Synthesis and Conclusive Insights on STI Diagnostics

In summary, the landscape of sexually transmitted diseases diagnostics is undergoing transformative changes powered by technological breakthroughs, evolving regulatory frameworks, and an increased emphasis on precision medicine. The analysis provided in this report uncovers multifaceted segmentation across disease types, test modalities, sample types, end-user classifications, and distribution channels - all of which contribute to a comprehensive understanding of market dynamics and strategic opportunities. Regional insights highlight significant discrepancies in market maturity and adoption rates, while leading companies continuously push the envelope in both innovation and application. The integration of state-of-the-art diagnostic techniques with effective market strategies is paving the way for improved patient outcomes and enhanced public health responses. This synthesis bridges the gap between clinical innovation and market trends, urging stakeholders to focus on sustained investment in evolving technologies and strategic partnerships. Thus, the confluence of these factors not only solidifies the current market status but also paves the way for future advancements in the detection and management of sexually transmitted diseases.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidence and awareness of STDs globally
    • 5.1.1.2. Growing implementation of supportive policies and initiatives from governments and health organizations
    • 5.1.1.3. Expanded access to healthcare services facilitates greater availability and use of STD diagnostic services across globe
  • 5.1.2. Restraints
    • 5.1.2.1. Issues related to ability to keep diagnostic tests up-to-date with evolving strains and emerging pathogens
  • 5.1.3. Opportunities
    • 5.1.3.1. Growing potential with partnerships between diagnostic companies and healthcare providers or NGOs
    • 5.1.3.2. Innovations in point-of-care testing to reduce the need for specialized laboratories and healthcare personnel
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns associated with complex regulatory environments across different regions
• 5.2. Market Segmentation Analysis
  • 5.2.1. Disease Type: Increasing need for nucleic acid amplification tests in chlamydia owing to high sensitivity and specificity
  • 5.2.2. End-User: Proliferating applications of STD diagnostics in hospitals and clinics for accurate and timely diagnosis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Sexually Transmitted Diseases Diagnostics Market, by Disease Type

• 6.1. Introduction
• 6.2. Chlamydia
• 6.3. Gonorrhea
• 6.4. Herpes Simplex Virus (HSV)
• 6.5. Human Immunodeficiency Virus (HIV)
• 6.6. Human Papillomavirus (HPV)
• 6.7. Syphilis

7. Sexually Transmitted Diseases Diagnostics Market, by Test Types

• 7.1. Introduction
• 7.2. Laboratory Testing
  • 7.2.1. Enzyme-linked Immunosorbent Assay (ELISA)
  • 7.2.2. Nucleic Acid Amplification Tests (NAATs)
  • 7.2.3. Rapid Plasma Reagin (RPR)
• 7.3. Point-of-Care Testing
  • 7.3.1. Home Testing Kits
  • 7.3.2. Rapid Tests

8. Sexually Transmitted Diseases Diagnostics Market, by Sample Type

• 8.1. Introduction
• 8.2. Blood
• 8.3. Urine
• 8.4. Vaginal Swabs

9. Sexually Transmitted Diseases Diagnostics Market, by End-User

• 9.1. Introduction
• 9.2. Homecare Settings
• 9.3. Hospitals & Clinics
• 9.4. Point-of-Care Settings
• 9.5. Public Health Labs
• 9.6. Research Laboratories

10. Sexually Transmitted Diseases Diagnostics Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Direct Sales
• 10.3. Distributors

11. Americas Sexually Transmitted Diseases Diagnostics Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Sexually Transmitted Diseases Diagnostics Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Sexually Transmitted Diseases Diagnostics Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2024
• 14.2. FPNV Positioning Matrix, 2024
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Labcorp and NOWDiagnostics collaborate to expand rapid syphilis testing amid rising STI cases nationwide
  • 14.3.2. Sherlock Biosciences innovative clinical trial for rapid OTC STI diagnostics
  • 14.3.3. Binx Health secures USD 65 million to enhance rapid point-of-care STI diagnostics
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Astra Biotech GmbH
• 3. Becton Dickinson and company
• 4. Bio-Rad Laboratories, Inc.
• 5. bioMerieux SA
• 6. Danaher Corporation
• 7. Daye Limited
• 8. Diasorin S.p.A
• 9. F. Hoffmann-La Roche Ltd.
• 10. Geneproof
• 11. Hologic Inc.
• 12. Jiangsu BioPerfectus Technologies Co., Ltd
• 13. Liferiver Bio-Tech Corp.
• 14. MedMira Inc.
• 15. Merck KGaA
• 16. Meridian Bioscience Inc.
• 17. Mylab Discovery Solutions Pvt. Ltd.
• 18. Novartis AG
• 19. OraSure Technologies, Inc.
• 20. Qiagen Inc.
• 21. Quest Consumer Inc.
• 22. Sansure Biotech Inc.
• 23. Seegene Inc.
• 24. Siemens Healthineers AG
• 25. Thermo Fisher Scientific, Inc.